Skip to content

Idexx Laboratories IDXX LPD — Goodwill

Other segment segments

CAG
$374.45M+2.0%
Water segment revenue
$18.41M+1.6%

Similar metrics at other companies

GE HealthCare Technologies logo
GEHCPDx — Goodwill
$2.74B-0.3%
Ashland logo
ASHLife Sciences — Goodwill
$462M-42.8%
Boston Omaha logo
BOCLMH — Goodwill
$130.9M0.0%
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Goodwill
$5.08B+6.1%
Revvity logo
RVTYLife Sciences — Goodwill
$4.75B+3.9%
IDEX logo
IEXFSDP — Goodwill
$373.5M+2.2%

Other financials

Income statement

See full
Revenue$1.1B+14.3%
Gross profit$722.7M+15.9%
Operating income$362.6M+14.5%
Net income$278.4M+14.7%
EPS (diluted)$3.47+17.2%

Balance sheet

See full
Cash & equivalents$200.5M+22.3%
Total debt$575.5M-22.2%
Total equity$1.6B+7.5%
Total assets$3.4B+5.3%

Cash flow

See full
Operating cash flow$266.2M+11.9%
CapEx$32.0M+6.5%
Free cash flow$234.3M+12.7%

Valuation

See full
Market cap$43.5B+2.0%
Enterprise value$43.88B+1.7%
P/E39.7×-3.6×
P/S9.8×-0.8×

Profitability

See full
Gross margin62.1%+0.8pp
Operating margin31.6%+2.5pp
Net margin24.6%+1.9pp
FCF margin24.4%+2.8pp

Returns & leverage

See full
Return on equity72.9%+13.6pp
Debt / equity0.4×-0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Idexx Laboratories’s 10-K, filed February 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Idexx Laboratories's lpd — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Idexx Laboratories's LPD — goodwill?
Idexx Laboratories (IDXX) reported LPD — goodwill of $15.12M in Q4 2025.
How has Idexx Laboratories's LPD — goodwill changed year-over-year?
Idexx Laboratories's LPD — goodwill increased by 12.1% year-over-year, from $13.48M to $15.12M.
What does LPD — goodwill mean?
This represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations specifically attributed to the Livestock and Poultry Diagnostics segment. It reflects the premium paid for intangible assets such as brand reputation, customer relationships, and proprietary diagnostic technology within the animal health market.